Abstract
To confirm several recent studies pointing to loss of heterozygosity (LOH) at BRCA2 as a prognostic factor in sporadic breast cancer, we examined this genetic alteration in a large series of human primary breast tumours for which long-term patient outcomes were known. LOH at BRCA2 correlated only with low oestrogen and progesterone receptor content. Univariate analysis of metastasis-free survival and overall survival (log-rank test) showed no link with BRCA2 status (P = 0.34, P = 0.29 respectively). LOH at BRCA2 does not therefore appear to be a major prognostic marker in sporadic breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bièche, I., Noguès, C., Rivoilan, S. et al. Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma. Br J Cancer 76, 1416–1418 (1997). https://doi.org/10.1038/bjc.1997.572
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.572
This article is cited by
-
Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53codon 72 Arg>Pro polymorphism
Breast Cancer Research (2007)
-
Frequent allelic losses at 11q24.1–q25 in young women with breast cancer: association with poor survival
British Journal of Cancer (1999)
-
Overexpression of BRCA2 gene in sporadic breast tumours
Oncogene (1999)
-
Bilateral nonpalpable breast carcinomas in a patient withbrca2 germ line mutation and past history of osteosarcoma
Breast Cancer (1999)
